Vifor Pharma (VIFN.SW) Stock Price
Vifor Pharma Price
Revenue at Vifor Pharma has contracted by 1.2% per year over the past 19 years to 1.82 B CHF. Earnings per share have grown at 5.4% per year over the last 19 years. For Vifor Pharma, the net margin of 7.9% is down versus 85.5% a few years ago. At today's price the dividend yield works out to roughly 1.20%. The payout ratio is around 81% of earnings. The dividend has grown at 10.5% per year over the past 18 years.
Vifor Pharma stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Vifor Pharma business model & stock analysis
Frequently asked questions about Vifor Pharma
The business model of Vifor Pharma AG focuses on the development, production, and commercialization of pharmaceutical products. As a global healthcare company, Vifor Pharma AG specializes in the field of iron deficiency, nephrology, and cardio-renal therapies. They aim to improve the quality of life for patients suffering from various medical conditions, including chronic kidney disease, iron deficiency anemia, and renal diseases. Vifor Pharma AG collaborates with healthcare professionals and organizations worldwide to bring innovative and effective treatments to market. By leveraging their expertise and research capabilities, Vifor Pharma AG continues to drive advancements in the field of pharmaceuticals and improve patient outcomes.
Vifor Pharma AG is primarily active in the pharmaceutical industry.
The main competitors of Vifor Pharma AG in the market include companies like Novartis, Roche, Sanofi, and AstraZeneca. These companies operate in similar therapeutic areas and engage in the development and commercialization of pharmaceutical products. Vifor Pharma AG competes with these companies through its innovative and high-quality offerings, strategic partnerships, and strong market presence. By continuously adapting and expanding its product portfolio, Vifor Pharma AG aims to maintain its competitive position within the pharmaceutical industry.
Vifor Pharma AG, a leading global pharmaceutical company, has a rich history and background. Established in 1872 and headquartered in Switzerland, Vifor Pharma focuses on innovative treatments for patients suffering from iron deficiency, nephrology, and cardio-renal disorders. The company has played a pivotal role in healthcare advancements, leveraging its expertise to develop high-quality and effective pharmaceutical products. Vifor Pharma operates globally, collaborating with healthcare professionals to improve patients' well-being. Committed to research, development, and sustainable growth, Vifor Pharma aims to enhance the lives of individuals worldwide through its innovative solutions in the medical field.
Vifor Pharma AG, a renowned pharmaceutical company, has achieved several significant milestones throughout its existence. Notably, it successfully developed and launched a groundbreaking medication for the treatment of iron deficiency anemia (IDA) called Ferinject®. This innovative intravenous iron replacement therapy has transformed patient care worldwide. Vifor Pharma AG has also made strides in the field of nephrology, advancing the treatment of chronic kidney disease (CKD) and associated complications. With a strong focus on research and development, Vifor Pharma AG continues to seek out new therapeutic options and strategic partnerships to further enhance patient outcomes and improve global healthcare.
Vifor Pharma AG is primarily present in various countries and regions worldwide. Its presence can be seen in Europe, North America, and certain parts of Asia. The company operates in diverse markets, including Switzerland, Germany, Austria, France, the United Kingdom, the United States, China, and Japan. With a global reach, Vifor Pharma AG has established itself as a leading pharmaceutical player in these regions, offering innovative healthcare solutions and improving patient outcomes.
Vifor Pharma AG represents a set of core values and corporate philosophy that guides its operations. The company's values include a strong commitment to patients, healthcare providers, and employees. Vifor Pharma AG strives to make a positive impact on patients' lives through innovative healthcare solutions. The company's corporate philosophy centers around trust, integrity, and excellence. Vifor Pharma AG focuses on continuous improvement and delivering value to its stakeholders. With a patient-centric approach, Vifor Pharma AG aims to enhance patient outcomes and drive sustainable growth in the pharmaceutical industry.
11 analysts currently rate the Vifor Pharma stock: 0 recommend buying, 4 holding and 7 selling.
Converted at the current exchange rate, the Vifor Pharma share trades at 179.41 EUR (166.15 CHF).
The Vifor Pharma share (VIFN.SW) is listed on 5 stock exchanges, including: London (0RPD.L), SIX (Zürich) (VIFN.SW), Frankfurt (G2AA.F), München (G2AA.MU), Düsseldorf (G2AA.DU).
Vifor Pharma AG is a Swiss pharmaceutical company specializing in the research, development, and marketing of medicines for patients with kidney diseases, iron deficiency anemia, and other important therapeutic areas. The company operates various divisions worldwide and is a leading provider of products in the healthcare industry.
The revenue cannot currently be calculated for Vifor Pharma.
The profit cannot currently be calculated for Vifor Pharma.
The P/E ratio cannot be calculated for Vifor Pharma at the moment.
The P/S cannot be calculated for Vifor Pharma currently.
The Eulerpool Quality Score for Vifor Pharma is 3/10.
The ISIN of Vifor Pharma is CH0364749348. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Vifor Pharma is A2DRZ4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Vifor Pharma is VIFN.SW. The ticker symbol is used to trade Vifor Pharma shares on the stock exchange.
Vifor Pharma stock
Vifor Pharma Peer Group
Vifor Pharma Ticker
Vifor Pharma FIGI
All fundamentals and in-depth analysis of Vifor Pharma
Our stock analysis for Vifor Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vifor Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.